M
M. Andreoletti
Publications - 27
Citations - 1155
M. Andreoletti is an academic researcher. The author has contributed to research in topics: Entecavir & Cohort study. The author has an hindex of 9, co-authored 25 publications receiving 1070 citations.
Papers
More filters
Journal ArticleDOI
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
Anna Ludovica Fracanzani,Luca Valenti,Elisabetta Bugianesi,M. Andreoletti,Agostino Colli,Ester Vanni,Cristina Bertelli,Erika Fatta,D. Bignamini,Giulio Marchesini,Silvia Fargion +10 more
TL;DR: Normal ALT is not a valuable criterion to exclude patients from liver biopsy, and Alterations in glucose metabolism and insulin resistance in subjects with normal ALT should also be considered in the selection of NAFLD cases for histological assessment of disease severity and progression.
Journal ArticleDOI
Severe Liver Fibrosis or Cirrhosis: Accuracy of US for Detection—Analysis of 300 Cases
Agostino Colli,Mirella Fraquelli,M. Andreoletti,Barbara F. M. Marino,Enrico Zuccoli,Dario Conte +5 more
TL;DR: US determination of liver surface nodularity is an accurate method for identifying the subset of asymptomatic patients with severe liver fibrosis or cirrhosis, which indicates a worse prognosis.
Journal ArticleDOI
Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus
Dario Conte,Domenico Manachino,Agostino Colli,Andrea Guala,Giampiero Aimo,M. Andreoletti,Maura Corsetti,Mirella Fraquelli +7 more
TL;DR: The prevalence of genetic hemochromatosis in patients with diabetes from northern Italy and in an age- and sex-matched control group was studied and the accuracy of serum ferritin levels and transferrin saturation in estimating the prevalence of hemochROMatosis was evaluated.
Journal ArticleDOI
Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C.
Agostino Colli,A. Colucci,Silvia Paggi,Mirella Fraquelli,Sara Massironi,M. Andreoletti,Vittorio Michela,Dario Conte +7 more
TL;DR: The model can correctly identify 67% of patients with a high (>75%) or low (<10%) probability of cirrhosis, leaving only 33% of the patients still requiring liver biopsy.
Journal ArticleDOI
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis
Pietro Lampertico,Roberta Soffredini,Cihan Yurdaydin,Ramazan Idilman,George V. Papatheodoridis,Aikaterini Margariti,Maria Buti,R. Esteban,Serena Zaltron,A. Vavassori,Francesco Castelli,Mauro Viganò,M.G. Rumi,Maria Cristina Vinci,Luca S. Belli,Giuliana Cologni,Marco Rizzi,M. Milanese,Mario Strazzabosco,Eliseo Minola,Alessia Giorgini,Massimo Zuin,A. Salmi,Silvia Colombo,O. Fracassetti,P. Del Poggio,Savino Bruno,Luisa Pasulo,Stefano Fagiuoli,M. Andreoletti,A. Colli,Alberto Colombo,Giorgio Bellati,Carlo Magni,E. Angeli,Guido Gubertini,Giuliano Rizzardini,Massimo Fasano,Teresa Santantonio,Natalia Terreni,Giancarlo Spinzi,Floriana Facchetti,Federica Invernizzi,G. Mangia,M. Colombo +44 more